Download App
Help CenterSubscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532526 NSE: DISHMAN Pharmaceuticals & Drugs | Small Cap | Dishman Pharma(Amalg Share Price

BSE Share Price
Not Listed

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532526 NSE: DISHMAN Pharmaceuticals & Drugs | Small Cap | Dishman Pharma(Amalg Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹4,859 Cr.
Current Price
₹0
52-Week Low / High
₹278 / 304
TTM EPS
₹10
TTM Sales
₹1,609 Cr.
Book Value per Share
₹103.5
P/E Ratio
30.15
Industry PE
54.2
Price to Book (P/B)
2.91
Price to Sales (P/S)
3.02
EV/EBITDA
12.43
Dividend Yield
INF%
Profitability Efficiency
Return on Equity (ROE)
12.77%
Return on Capital Employed (ROCE)
14.40%
Return on Assets (ROA)
5.91%
Operating Profit Margin
25.7%
Net Profit Margin
10.71%
Gross Profit Margin
21.4%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
3.69%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
31.21%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
42.79%
Asset Quality
Promoter Holding
61.40%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹1,638 Cr.
Equity
₹32.3 Cr.
Face Value
₹2
All Time Low / High
₹16.25 / 346.25

Dishman Pharmaceuticals & Chemicals . - (Amalgamated) stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation ⓘ

Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16TTM
ROCE % ⓘ14.1%12.9%15.7%11.6%7.9%10.6%12.3%14.7%12.4%12.6%-

Growth Parameters ⓘ
Sales ⓘ275359416353421463485473492510417
Sales YoY Gr.-30.5%15.8%-15.2%19.3%10.1%4.6%-2.3%4%3.7%-
Adj EPS ⓘ3.83.76.34.32.43.24.15.33.35.24.1
YoY Gr.--1.9%71.5%-32.7%-43.2%31%30.3%28.3%-38.1%59.2%-
BVPS (₹) ⓘ18.528.33437.839.641.644.849.351.756.4295.5
Adj Net
Profit ⓘ		54.258.910268.839.151.166.785.65384.266
Cash Flow from Ops. ⓘ21.242.590.811011825028.312614.5125-
Debt/CF from Ops. ⓘ14.16.23.244.8218.54.243.45-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ7.1%3.9%1.7%3.7%
Adj EPS ⓘ3.7%16.6%8.1%59.2%
BVPSⓘ13.2%7.3%7.9%9%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16TTM
Return on
Equity % ⓘ		24.616.320.311.86.27.89.511.26.59.62.3
Op. Profit
Mgn % ⓘ		25.725.636.133.32433.43637.230.133.532.5
Net Profit
Mgn % ⓘ		19.716.424.619.59.31113.818.110.816.515.7
Debt to
Equity ⓘ		1.10.60.50.70.90.70.70.70.80.7-
Working Cap
Days ⓘ		325307270347417436406467564638287
Cash Conv.
Cycle ⓘ		183168133101796153508591118

Valuation of Dishman Pharma(Amalg - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *35.7630.3117.2611.462.462.420.570.570.570.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Sales578.57803.081,062.36915.361,031.361,124.111,272.221,385.321,588.741,596.05
Operating Expenses ⓘ + 463.45650.21801.14712.43829.97899.65982.101,053.211,276.031,185.73
Manufacturing Costs54.5757.3780.2381.0479.1190.14108.82117.72137.89152.46
Material Costs199.79293.40324.28276.75362.84384.53375.85373.42549.48336.30
Employee Cost 135.57211.59267.45248.98280.35294.10350.91412.33423.21535.49
Other Costs ⓘ 73.5187.85129.18105.66107.68130.87146.51149.75165.45161.48
Operating Profit ⓘ 115.12152.87261.22202.93201.38224.46290.12332.11312.71410.32
Operating Profit Margin (%) 19.9%19.0%24.6%22.2%19.5%20.0%22.8%24.0%19.7%25.7%
Other Income ⓘ + 25.9951.078.5137.0413.8912.9217.8224.9186.9126.54
Exceptional Items ⓘ 0000000000
Interest ⓘ 18.9433.9149.3548.0355.7372.9478.8292.0589.7194.44
Depreciation ⓘ 26.3147.1962.9159.4268.7676.5283.84108.56150.71109.06
Profit Before Tax ⓘ 95.87122.85157.46132.5390.7787.91145.28156.40159.20233.36
Tax ⓘ 3.201.3310.7214.9510.7631.1544.9947.1339.4462.36
Profit After Tax 92.67121.51146.74117.5880.0156.76100.29109.27119.76171
PAT Margin (%) 16.0%15.1%13.8%12.8%7.8%5.1%7.9%7.9%7.5%10.7%
Adjusted EPS (₹)6.47.69.17.35.03.56.26.87.410.6
Dividend Payout Ratio (%)7.80%6.60%6.60%8.20%12.10%17.10%9.70%8.90%13.50%9.40%
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16

Equity and Liabilities

Shareholders Fund + 314.96550.02702.64776.70877.60928.841,030.801,177.201,237.791,451.55
Share Capital ⓘ 14.4415.9416.1416.1416.1416.1416.1416.1416.1416.14
Reserves ⓘ 300.52534.09686.50760.56861.47912.701,014.661,161.071,221.651,435.41
Debt +560.95657.98733.56786.59728.15745.62764.23790.75737.01841.32
Long Term Debt560.95657.98733.56786.59444.26512.05433.63412.08330.19418.94
Short Term Debt0000283.89233.57330.60378.66406.82422.38
Minority Interest0000000000.44
Trade Payables65.5760.2849.4879.59171.44165.79105.5584.23151.4486.97
Others Liabilities ⓘ 219.39225.31166.72146.93360.69417.12390.53575.51682.69600.25
Total Liabilities ⓘ 1,160.861,493.601,652.401,789.802,137.882,257.362,291.112,627.692,808.932,980.53

Fixed Assets

Net Fixed Assets ⓘ +537.98684.46778.08842.941,012.041,033.111,372.871,505.171,440.921,545.01
Gross Block607.89796.24973.351,091.031,339.891,472.861,896.812,193.162,254.362,491.20
Accumulated Depreciation69.91111.78195.27248.09327.85439.75523.93687.99813.44946.19
CWIP ⓘ 64.98148.47222.72357.43306.95418.2597.3678.85141.8185.40
Investments ⓘ 14.021.331.381.421.4126.3024.9124.9124.9525.04
Inventories297.78304.73303.96242.35270.22267.06338.27423.26448.26483.11
Trade Receivables125.16204.18149.38113.12170.07186.9772.91143.97217.11152.33
Cash Equivalents 35.5537.1045.1645.4542.5124.042135.2936.2062.20
Others Assets ⓘ 85.39113.33151.73187.09334.70301.63363.78416.24499.68627.44
Total Assets ⓘ 1,160.861,493.601,652.401,789.802,137.882,257.362,291.112,627.692,808.932,980.53
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Cash Flow From Operating Activity ⓘ + 42.7349.44131.76302.18202.78153.58165.14344.50293.69278.64
PBT ⓘ 95.97122.85157.46132.5390.7787.91145.28156.40159.20233.36
Adjustment ⓘ 36.2376.42-0.76142.1774.3273.02155.68221.93160.94186.30
Changes in Working Capital ⓘ -83.48-138.57-10.5646.6151.286.39-116.75-3.4317.63-83.48
Tax Paid ⓘ -6.08-9.46-14.26-17.41-13.59-13.75-19.08-30.40-44.08-57.54
Cash Flow From Investing Activity ⓘ + -417.57-253.22-167.61-294.91-231.18-104-117.28-256.80-158.06-152.89
Capex -415.95-269.41-168.31-304.18-240.24-94.50-134.51-288.42-137.69-120.86
Net Investments -6.8512.680.050.050-22.7700-14.760
Others ⓘ 5.233.510.659.229.0613.2717.2331.62-5.61-32.03
Cash Flow From Financing Activity ⓘ + 275.21205.3443.91-6.9825.45-68.04-50.15-74.06-142.02-94.10
Net Proceeds from Shares ⓘ 320.451.755.81000000
Net Proceeds from Borrowing ⓘ 302.20206.6212645.4263.0367.80-103.9940.20-69.63-5.43
Interest Paid ⓘ -18.94-33.91-55.46-51.72-54.74-74.25-78.37-89.30-89.23-71.97
Dividend Paid ⓘ -4.82-7.63-8.07-9.68-9.68-9.68-9.68-9.68-9.67-32.27
Others ⓘ -6.2419.80-20.313.2026.85-51.90141.90-15.2826.5115.57
Net Cash Flow ⓘ -99.631.558.060.29-2.95-18.46-2.2913.64-6.3931.65
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Ratios
ROE (%)38.1728.6723.7116.039.746.3210.299.959.9612.77
ROCE (%)16.714.9815.5812.058.869.1512.2512.3211.5414.4
Asset Turnover Ratio0.670.610.680.530.530.510.560.570.590.55
PAT to CFO Conversion(x)0.460.410.92.572.532.711.653.152.451.63
Working Capital Days
Receivable Days65.9074.1060.305249.9057.7037.1028.5041.3042.10
Inventory Days126.50135.50103.80108.3090.2086.8086.5099.9099.70106.10
Payable Days103.1078.3061.8085.10126.30160.10131.8092.8078.30129.40

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) FAQs

The current trading price of Dishman Pharma(Amalg on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Dishman Pharma(Amalg stood at ₹4,858.8 Cr

The latest P/E ratio of Dishman Pharma(Amalg as of 31-Dec-1969 is 74.11.

The latest P/B ratio of Dishman Pharma(Amalg as of 31-Dec-1969 is 1.02.

The 52-week high of Dishman Pharma(Amalg is ₹304.3 and the 52-week low is ₹278.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dishman Pharma(Amalg is ₹417 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) is a average quality company.

No data found

No data found

About Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated)

Dishman Pharmaceuticals and Chemicals Limited (DPCL) was incorporated in 1983 as a research-oriented company. Later in 1989 the company started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds. The company became a global market leader and earned the status of the “Quat Company”. In the period of 10 years the production capacity was increased from 10MT per annum to 1500 Mt per annum.

In the year 1995, the company entered into a joint ventured with Schütz & Co, Germany and formed Schütz Dishman Biotech. This company manufactures Chlorhexidine Base, Chlorhexidine HCl, Chlorhexidine Acetate and Chlorhexidine Gluconate solution to cater European market. In 1995-96, the company expanded its activities for the development of many intermediates and APIs. In 1998 in order to penetrate in European and US market, the company formed two wholly-owned subsidiaries Dishman Europe and Dishman USA Inc. In 1998, the company forayed into contract research and manufacture sector. Within a period of 5 years DPCL was able to several contract research and manufacturing projects and later emerged as India’s leading CMO organization (Contract Manufacturing Outsourcing).

Headquartered at Ahmedabad, the company owns three manufacturing units, two located at Bavla and one at Naroda. Presently the company is manufactures a range of Bulk APIs, Intermediates, Specialties and Quats. The company has representative office located at Germany, Italy and Turkey.

DPCL is engaged in the manufacture of active pharmaceutical ingredients (APIs) intermediates. The Company operates in two segments: contract research and contract manufacturing (CRAMS), and bulk drugs, intermediates, quats and specialty chemicals. It provides a range of products to the global market, including a range of reagents, specialty chemicals, APIs and their intermediates.

Business units:

Dishman Specialty Chemicals, which manufactures Phase Transfer Catalysts;

Dishman Vitamins and Chemicals, which manufactures Vitamin D2, Vitamin D3, Vitamin D analogues, cholesterol and laolin related products for pharmaceutical, cosmetic and related markets,

Dishman Disinfectants, which manufactures antiseptic and disinfectant formulations.

The products manufactured by the company include bulk drugs, phase transfer catalyst and fine chemicals

 

You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now